RYAN CASEY: Open Payments
NPI 1144908252 · MERIDIAN, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$751 in 32 payments from 15 companies in 2025. Trend: 2023 $19 · 2024 $332 · 2025 $751
Food & beverage: $751
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 2 | $159 |
| Novo Nordisk Inc | 8 | $139 |
| ABBVIE INC. | 4 | $81 |
| Lilly USA, LLC | 4 | $80 |
| Exact Sciences Corporation | 3 | $66 |
| AstraZeneca Pharmaceuticals LP | 2 | $40 |
| Novartis Pharmaceuticals Corporation | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $21 |
Products named: REPATHA, Wegovy, Cologuard Collection Kit, MOUNJARO, QULIPTA, Rybelsus, FARXIGA, JARDIANCE.
Industry payments across ID — which companies pay providers there.
